Daré Bioscience, Inc.
DARE
$2.04
-$0.04-1.92%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -17.70K | 25.90K | 9.80K | 1.88M | 2.84M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -17.70K | 25.90K | 9.80K | 1.88M | 2.84M |
| Cost of Revenue | 16.54M | 16.54M | 17.61M | 24.95M | 24.95M |
| Gross Profit | -16.56M | -16.52M | -17.60M | -23.07M | -22.11M |
| SG&A Expenses | 8.72M | 8.79M | 9.16M | 10.11M | 10.77M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.46M | 22.04M | 23.46M | 24.92M | 29.59M |
| Operating Income | -18.48M | -22.01M | -23.45M | -23.03M | -26.75M |
| Income Before Tax | -18.60M | -1.68M | -4.05M | -3.60M | -7.20M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.60 | -1.68 | -4.05 | -3.60 | -7.20 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.60M | -1.68M | -4.05M | -3.60M | -7.20M |
| EBIT | -18.48M | -22.01M | -23.45M | -23.03M | -26.75M |
| EBITDA | -17.84M | -21.82M | -23.41M | -22.99M | -26.70M |
| EPS Basic | -2.19 | -0.20 | -0.51 | -0.52 | -1.06 |
| Normalized Basic EPS | -1.42 | -0.17 | -0.37 | -0.31 | -0.64 |
| EPS Diluted | -2.19 | -0.22 | -0.53 | -0.53 | -1.08 |
| Normalized Diluted EPS | -1.42 | -0.18 | -0.37 | -0.31 | -0.65 |
| Average Basic Shares Outstanding | 34.18M | 33.72M | 33.34M | 32.62M | 31.67M |
| Average Diluted Shares Outstanding | 34.18M | 33.79M | 33.41M | 32.68M | 31.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |